Abstract:Background: Pantothenate kinase-associated neurodegeneration (PKAN) is a rare autosomal recessive genetic disorder of PANK2, which enables mitochondrial synthesis of coenzyme A. Its loss causes neurodegeneration with iron accumulation primarily in motor-related brain areas. Symptoms include dystonia, parkinsonism, and other disabilities. PKAN has been categorized as classic PKAN, with an age of onset ≤ 10 years, rapid progression, and early disability or death; and atypical PKAN, with later onset, slower progression, generally milder, and more diverse symptom manifestations. Available treatments are mostly palliative. Information on the lived experience of patients with PKAN and their caregivers or on community-level disease burden is limited. It is necessary to engage patients as partners to expand our understanding and improve clinical outcomes. This patient-oriented research study used multiple-choice and free-form question surveys distributed by patient organizations to collect information on the manifestations and disease burden of PKAN. It also assessed respondents' experiences and preferences with clinical research to inform future clinical trials. Results: The analysis included 166 surveys. Most respondents (87%) were parents of a patient with PKAN and 7% were patients, with 80% from Europe and North America. The study cohort included 85 patients with classic PKAN (mean ± SD age of onset 4.4 ± 2.79 years), 65 with atypical PKAN (13.8 ± 4.79 years), and 16 identified as "not sure". Respondents reported gait disturbances and dystonia most often in both groups, with 44% unable to walk. The classic PKAN group reported more speech, swallowing, and visual difficulties and more severe motor problems than the atypical PKAN group. Dystonia and speech/swallowing difficulties were reported as the most challenging symptoms. Most respondents reported using multiple medications, primarily anticonvulsants and antiparkinsonian drugs, and about half had participated in a clinical research study. Study participants reported the most difficulties with the physical exertion associated with imaging assessments and travel to assessment sites. Conclusions: The survey results support the dichotomy between classic and atypical PKAN that extends beyond the age of onset. Inclusion of patients as clinical research partners shows promise as a pathway to improving clinical trials and providing more efficacious PKAN therapies.

[Clinical characteristics and molecular pathogenesis of pantothenate kinase-associated neurodegenerative disease].

Novel compound heterozygous mutations in the PANK2 gene in a Chinese patient with atypical pantothenate kinase-associated neurodegeneration.

Clinical characteristics of pantothenate kinase-associated neurodegeneration(report of 1 case)

Novel PANK2 Mutations in Patients With Pantothenate Kinase-Associated Neurodegeneration and the Genotype–Phenotype Correlation

Phenotypic and Genotypic Features of Twenty Children with Classic Pantothenate Kinase-Associated Neurodegeneration

Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration

The first Vietnamese patient who presented late onset of pantothenate kinase-associated neurodegeneration diagnosed by whole exome sequencing: A case report

PANK2 P.a170fs：a Novel Pathogenetic Mutation, Compound with PANK2 P.r440p, Causing Pantothenate Kinase Associated Neurodegeneration in a Chinese Family.

Patient and caregiver experiences with pantothenate kinase-associated neurodegeneration (PKAN): results from a patient community survey

Novel PANK2 mutation in a Chinese boy with PANK2-associated neurodegeneration: A case report and review of Chinese cases.

Transcranial sonography in pantothenate kinase-associated neurodegeneration

Mitochondrial iron deficiency triggers cytosolic iron overload in PKAN hiPS-derived astrocytes

A Familial Late-Onset Hereditary Ataxia Mimicking Pontocerebellar Hypoplasia Caused by A Novel Tsen54 Mutation

[Progress of Clinical and Genetic Research on Distal Hereditary Motor Neuropathy].

Research progress of β-propeller protein-associated neurodegeneration

Neuronal Ablation of CoA Synthase Causes Motor Deficits, Iron Dyshomeostasis, and Mitochondrial Dysfunctions in a CoPAN Mouse Model

Case Report: Novel Compound Heterozygous Variants in the PANK2 Gene in a Chinese Patient Diagnosed with ASD and ADHD

Pantothenate kinase 2 interacts with PINK1 to regulate mitochondrial quality control via acetyl-CoA metabolism

Concurrent PANK2 and OCA2 variants in a patient with retinal dystrophy, hypopigmented irides and neurodegeneration

Neurodegeneration with brain iron accumulation: Insights into the mitochondria dysregulation

PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes